Somalogic Operating Co., Inc.
Boulder, CO Doing business as CM Life Sciences II Inc. Part of Standard Biotools Inc.
- UEI
- CTK7E4CB43M7
- CAGE
- 3Q4R1
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Standard Biotools Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Standard Biotools Inc. · South San Francisco, CA
Q7U7QSDD32W4
-
Parent
Standard Biotools Inc. · South San Francisco, CA
Q7U7QSDD32W4
- SAM.gov registration date
- Physical address
- 2945 Wilderness Pl, Boulder, CO 80301, USA
- Website
- somalogic.com
- Founded
- 2000
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $698,718 |
| FY2025 | $3,090,746 |
| FY2024 | $1,579,295 |
| FY2023 | $5,309,687 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $653,718 | |
| 2 | Department of Veterans Affairs | $45,000 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The University Of Texas Southwestern Medical Center | R01HL153499 | $810,000 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Olink Proteomics Inc. | Waltham, MA | 541380 Testing Laboratories and Services |
| Quanterix Corporation | Billerica, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Proteinsimple | San Jose, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Alamar Biosciecnes, Inc. | Fremont, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Indevr, Inc. | Boulder, CO | 334516 Analytical Laboratory Instrument Manufacturing |
About the company
Somalogic Operating Co., Inc., doing business as CM Life Sciences II Inc., manufactures and delivers aptamer-based proteomics assay kits and high-throughput protein measurement services as a prime contractor to federal biomedical research agencies, competing on full-and-open basis with no set-asides. The company is a for-profit manufacturer based in Boulder, Colorado, and operates as a subsidiary of Standard Biotools Inc. (formerly Fluidigm); its proprietary SomaScan platform simultaneously measures up to 11,000 proteins in small-volume biosamples across plasma, serum, cerebrospinal fluid, urine, and cell and tissue variants.
Somalogic's federal footprint is heavily concentrated within the Department of Health and Human Services, with 17 distinct customer agencies but dominated by NIH research institutes and the FDA. The National Institute of Allergy and Infectious Diseases (26 awards, $8.5 million combined potential value) anchors the customer base, followed by the FDA (15 awards, $8 million) and the National Institute on Aging (15 awards, $4.4 million); these three customers account for the majority of both award count and potential value. The National Institute on Drug Abuse (9 awards, $3.5 million), National Heart Lung and Blood Institute (24 awards, $3.4 million), National Cancer Institute (11 awards, $612 thousand), and Department of Veterans Affairs round out the active NIH and federal health research set. The vendor has also received work from the Defense Health Agency (a $970 thousand definitive contract for psychological health biomarker validation using Custom Panel assays) and the Centers for Disease Control and Prevention (a $38 thousand small-business purchase order for female genital schistosomiasis biomarker screening). Combined potential value across all prime and sub awards reaches $31.1 million, with $24.5 million obligated to date.
Recent activity has declined year over year—12 awards in 2022 to 3 awarded in 2026 year-to-date—though the dollar volume has remained substantial. Four awards carrying combined potential value of $1 million reach ultimate completion in the next twenty-four months and face recompete risk. Somalogic competes almost exclusively as a prime (99% of awards) rather than as a subcontractor; a single grant sub-award appears in the source, a sub-recipient role under the University of Texas Southwestern Medical Center's federal grant for aptamer-based proteomics analysis.
Somalogic holds parent vehicle positions on an FDA Indefinite Delivery/Indefinite Quantity contract valued at $2.002 million (awarded September 2025, five-year term through September 2030) and historically has placed task orders under multiple FDA IDIQs, including contract 75F40120D00018 (5 delivery orders, $797 thousand combined value) and contract HHSN271201500010I (4 task orders, $611 thousand). Representative prime work includes a $2.053 million NIAID purchase order for 59 SomaScan 7K and 11K assay kits to support systems immunology research at the Center for Human Immunology (April 2025); a $721 thousand National Institute on Aging purchase order for 16 SomaScan 11K kits (September 2025); a $566 thousand NIA purchase order for protein measurements across 872 plasma samples from the Nutrition for Precision Health cohort (August 2023); a $970 thousand Defense Health Agency definitive contract for Custom Panel 100 assay services and SomaSignal test analysis to identify psychological health biomarkers in service members (May 2023); and a $90 thousand Veterans Integrated Service Network 5 definitive contract for SomaScan 11K platform analysis of frozen plasma aliquots from veterans with prostate cancer (July 2026). The FDA IDIQ has generated multiple delivery orders for proteomics analysis and genomic services, including $273 thousand (September 2025), $213 thousand (June 2023), $149 thousand (August 2026), and $40 thousand (June 2022) orders.
Work is performed across multiple Somalogic locations, including Boulder, Colorado (primary headquarters and analytical facility); Silver Spring, Maryland (FDA and NIH Clinical Center interface); and Bethesda, Maryland (NIH delivery point). The vendor's award portfolio spans biological product manufacturing (40 awards), research and development in biotechnology (28 awards), and testing laboratory services (16 awards), reflecting the dual character of the business—both kit and reagent sales and high-throughput analytical services. PSC distribution emphasizes reference laboratory testing (34 awards) and drugs and biologicals (26 awards). Awards are predominantly firm fixed price purchase orders and delivery orders, with a small number of definitive contracts. All but one award (the CDC purchase order designated as Total Small Business set-aside) carry no set-aside designation and reflect competitive or sole-source procurements in full-and-open categories.
Quick answers
Is Somalogic Operating Co., Inc. registered in SAM.gov?
Yes. Somalogic Operating Co., Inc.'s SAM.gov registration is active through April 9, 2027.
How much has Somalogic Operating Co., Inc. received in federal contracts?
Federal contracts obligated $3,090,746 to Somalogic Operating Co., Inc. in fiscal year 2025 and $10,678,447 in fiscal years 2023 through 2027.
How does Somalogic Operating Co., Inc. rank among federal contractors?
Somalogic Operating Co., Inc.'s parent company, Standard Biotools Inc., ranked #13 in NAICS 325414, #19 in PSC 6550 and #59 in NAICS 334516 in FY2025.
What is Somalogic Operating Co., Inc.'s most recent federal award?
Somalogic Operating Co., Inc.'s most recent federal contract award is EO 14398 (75F40126F19002), from Food and Drug Administration, on August 14, 2026.
On GovTribe
See Somalogic Operating Co., Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors